Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Free Cash Flow (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Free Cash Flow data on record, last reported at -$22.2 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 23.58% year-over-year to -$22.2 million; the TTM value through Dec 2025 reached -$99.0 million, down 51.53%, while the annual FY2025 figure was -$99.3 million, 51.98% down from the prior year.
  • Free Cash Flow reached -$22.2 million in Q4 2025 per CCCC's latest filing, up from -$31.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$5.2 million in Q2 2024 and bottomed at -$33.3 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$23.6 million, with a median of -$24.7 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: skyrocketed 73.82% in 2024, then plummeted 133.17% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$25.8 million in 2021, then dropped by 28.66% to -$33.2 million in 2022, then rose by 27.14% to -$24.2 million in 2023, then grew by 25.81% to -$17.9 million in 2024, then decreased by 23.58% to -$22.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$22.2 million in Q4 2025, -$31.5 million in Q3 2025, and -$12.1 million in Q2 2025.